Global Forzeset Tablets Market Strategic Research Report

Scope of the Report

The global Forzeset Tablets market size is predicted to grow from US$ 19.56 million in 2025 to US$ 104 million in 2032; it is expected to grow at a CAGR of 11.6% from 2026 to 2032.

Fulzerasib Tablets is an oral, highly selective, irreversible KRAS G12C inhibitor. It is mainly indicated for the treatment of locally advanced or metastatic non‑small cell lung cancer harboring the KRAS G12C mutation. By covalently binding to the cysteine residue of the mutant protein, it locks the KRAS protein in an inactive conformation, blocks the transduction of the downstream MAPK signaling pathway, and thereby inhibits tumor cell proliferation and survival, providing a new domestic targeted therapy option for Chinese patients with advanced lung cancer harboring the KRAS G12C mutation.In 2025, global Fulzerasib Tablets production reached approximately 12,000–15,000 bottles.

As the first domestically approved KRAS G12C inhibitor in China, Fulzerasib has taken an early lead in entering the market for the treatment of advanced non‑small cell lung cancer, filling the gap in targeted therapy for this target in China. The core driver of its market development lies in medical insurance access and the improvement of the payment system. Its inclusion in medical insurance with a substantial price reduction has significantly lowered the barrier for patients to access the drug and improved its availability and clinical penetration. At present, an intense competitive landscape among similar domestic drugs has taken shape. To maintain its competitiveness, Fulzerasib needs to build differentiated advantages in terms of pricing, indication expansion, and combination therapy regimens based on its clinical efficacy, safety profile, and commercialization network. As the domestic KRAS G12 inhibitor sector enters the volume‑expansion stage following medical insurance inclusion, market competition has shifted from "availability" to "superiority". Future growth will depend on the depth of medical insurance coverage, progress in indication expansion, clinical recognition, and commercial execution capabilities.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Forzeset Tablets market?

What factors are driving Forzeset Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Forzeset Tablets market opportunities vary by end market size?

How does Forzeset Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Forzeset Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 150mg
• 500mg

Segment by Combination Therapy

• Combined With Immune Checkpoint Inhibitors
• Combined With Anti‑Angiogenic Drugs

Segment by Production Technology

• Original
• Generic

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Advanced Non-Small Cell Lung Cancer (NSCLC)
• Brain Metastases
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Forzeset Tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Advanced Non-Small Cell Lung Cancer (NSCLC), Brain Metastases, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact